Thrombospondin 2, matrix Gla protein and digital analysis identified distinct fibroblast populations in fibrostenosing Crohn's disease.
Crohn Disease
/ pathology
Humans
Fibroblasts
/ metabolism
Extracellular Matrix Proteins
/ metabolism
Calcium-Binding Proteins
/ metabolism
Fibrosis
Thrombospondins
/ metabolism
Male
Matrix Gla Protein
Female
Adult
Middle Aged
Colitis, Ulcerative
/ pathology
MicroRNAs
/ genetics
Intestinal Mucosa
/ pathology
Aged
Immunohistochemistry
Crohn’s diseases
Digital analysis
Fibrostenosis
Matrix Gla protein
Myofibroblasts
Thrombospondin 2
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 Jun 2024
14 Jun 2024
Historique:
received:
20
12
2023
accepted:
11
06
2024
medline:
15
6
2024
pubmed:
15
6
2024
entrez:
14
6
2024
Statut:
epublish
Résumé
Fibrosis is an important complication in inflammatory bowel diseases. Previous studies suggest an important role of matrix Gla protein (MGP) and thrombospondin 2 (THBS2) in fibrosis in various organs. Our aim was to analyse their expression together with regulatory miRNAs in submucosal and subserosal fibroblasts in ulcerative colitis (UC) and Crohn's disease (CD) using immunohistochemistry and qPCR. Digital pathology was used to compare collagen fibre characteristics of submucosal and subserosal fibrosis. Immunohistochemistry showed expression of MGP, but not THBS2 in submucosa in UC and CD. In the subserosa, there was strong staining for both proteins in CD but not in UC. qPCR showed significant upregulation of THBS2 and MGP genes in CD subserosa compared to the submucosa. Digital pathology analysis revealed higher proportion of larger and thicker fibres that were more tortuous and reticulated in subserosal fibrosis compared to submucosal fibrosis. These results suggest distinct fibroblast populations in fibrostenosing CD, and are further supported by image analysis showing significant differences in the morphology and architecture of collagen fibres in submucosal fibrosis in comparison to subserosal fibrosis. Our study is the first to describe differences in submucosal and subserosal fibroblast populations, contributing to understanding of the pathogenesis of fibrostenosis in CD.
Identifiants
pubmed: 38877292
doi: 10.1038/s41598-024-64672-7
pii: 10.1038/s41598-024-64672-7
doi:
Substances chimiques
Extracellular Matrix Proteins
0
Calcium-Binding Proteins
0
thrombospondin 2
0
Thrombospondins
0
Matrix Gla Protein
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
13810Subventions
Organisme : Javna Agencija za Raziskovalno Dejavnost RS
ID : P3-0054
Organisme : Javna Agencija za Raziskovalno Dejavnost RS
ID : P3-0054
Organisme : Javna Agencija za Raziskovalno Dejavnost RS
ID : P3-0054
Organisme : Javna Agencija za Raziskovalno Dejavnost RS
ID : P3-0054
Informations de copyright
© 2024. The Author(s).
Références
Rieder, F. et al. European Crohn’s and Colitis organisation topical review on prediction, diagnosis and management of fibrostenosing Crohn’s disease. J. Crohn’s Colitis 10, 873–885 (2016).
doi: 10.1093/ecco-jcc/jjw055
Thia, K. T., Sandborn, W. J., Harmsen, W. S., Zinsmeister, A. R. & Loftus, E. V. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology 139, 1147–1155 (2010).
pubmed: 20637205
doi: 10.1053/j.gastro.2010.06.070
Gordon, I. O., Agrawal, N., Goldblum, J. R., Fiocchi, C. & Rieder, F. Fibrosis in ulcerative colitis. Inflamm. Bowel Dis. 20, 2198–2206 (2014).
pubmed: 24892966
doi: 10.1097/MIB.0000000000000080
Gordon, I. O. et al. Fibrosis in ulcerative colitis is directly linked to severity and chronicity of mucosal inflammation. Aliment. Pharmacol. Ther. 47, 922–939 (2018).
pubmed: 29411405
pmcid: 5842117
doi: 10.1111/apt.14526
Magro, F. et al. European consensus on the histopathology of inflammatory bowel disease. J. Crohn’s Colitis 7, 827–851 (2013).
doi: 10.1016/j.crohns.2013.06.001
Latella, G. & Rieder, F. Intestinal fibrosis. Curr. Opin. Gastroenterol. 33, 239–245 (2017).
pubmed: 28402994
pmcid: 5572460
doi: 10.1097/MOG.0000000000000363
Latella, G., Di Gregorio, J., Flati, V., Rieder, F. & Lawrance, I. C. Mechanisms of initiation and progression of intestinal fibrosis in IBD. Scand. J. Gastroenterol. 50, 53–65 (2014).
doi: 10.3109/00365521.2014.968863
Janson, D. G., Saintigny, G., Van Adrichem, A., Mahé, C. & El Ghalbzouri, A. Different gene expression patterns in human papillary and reticular fibroblasts. J Invest Dermatol 132, 2565–2572 (2012).
pubmed: 22696053
doi: 10.1038/jid.2012.192
Griffin, M. F., DesJardins-Park, H. E., Mascharak, S., Borrelli, M. R. & Longaker, M. T. Understanding the impact of fibroblast heterogeneity on skin fibrosis. Dis. Model Mech. 13 (2020).
Hu, M. S., Moore, A. L. & Longaker, M. T. A fibroblast is not a fibroblast is not a fibroblast. J Invest Dermatol 138, 729–730 (2018).
pubmed: 29579454
pmcid: 6540758
doi: 10.1016/j.jid.2017.10.012
Bensa, T., Tekkela, S. & Rognoni, E. Skin fibroblast functional heterogeneity in health and disease. J. Pathol. 260, 609–620 (2023).
pubmed: 37553730
doi: 10.1002/path.6159
Powell, D. W., Pinchuk, I. V., Saada, J. I., Chen, X. & Mifflin, R. C. Mesenchymal cells of the intestinal lamina propria. Annu. Rev. Physiol. 73, 213–237 (2011).
pubmed: 21054163
pmcid: 3754809
doi: 10.1146/annurev.physiol.70.113006.100646
Kinchen, J. et al. Structural remodeling of the human colonic mesenchyme in inflammatory bowel disease. Cell 175, 372-386.e17 (2018).
pubmed: 30270042
pmcid: 6176871
doi: 10.1016/j.cell.2018.08.067
Roulis, M. & Flavell, R. A. Fibroblasts and myofibroblasts of the intestinal lamina propria in physiology and disease. Differentiation 92, 116–131 (2016).
pubmed: 27165847
doi: 10.1016/j.diff.2016.05.002
Patil, D. T. & Odze, R. D. Biopsy diagnosis of colitis: an algorithmic approach. Virchows Archiv. 472, 67–80 (2018).
pubmed: 29177895
doi: 10.1007/s00428-017-2274-0
Jessurun, J. The differential diagnosis of acute colitis: Clues to a specific diagnosis. Surg. Pathol. Clin. 10, 863–885 (2017).
pubmed: 29103537
doi: 10.1016/j.path.2017.07.008
Zidar, N. Why do we have to look deep to understand diverticulitis?. Am. J. Gastroenterol. 114, 1347–1348 (2019).
pubmed: 31206399
doi: 10.14309/ajg.0000000000000297
Jerala, M., Hauptman, N., Kojc, N. & Zidar, N. Expression of fibrosis-related genes in liver and kidney fibrosis in comparison to inflammatory bowel diseases. Cells 11, 314 (2022).
pubmed: 35159124
pmcid: 8834113
doi: 10.3390/cells11030314
Nan, P. et al. Tumor-stroma TGF-β1-THBS2 feedback circuit drives pancreatic ductal adenocarcinoma progression via integrin αvβ3/CD36-mediated activation of the MAPK pathway. Cancer Lett. 528, 59–75 (2022).
pubmed: 34958892
doi: 10.1016/j.canlet.2021.12.025
Simantov, R., Febbraio, M. & Silverstein, R. L. The antiangiogenic effect of thrombospondin-2 is mediated by CD36 and modulated by histidine-rich glycoprotein. Matrix Biol. 24, 27–34 (2005).
pubmed: 15748999
doi: 10.1016/j.matbio.2004.11.005
Korosec, A. et al. Lineage identity and location within the dermis determine the function of papillary and reticular fibroblasts in human skin. J. Invest. Dermatol. 139, 342–351 (2019).
pubmed: 30179601
doi: 10.1016/j.jid.2018.07.033
Nezu, Y. et al. miR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma. Oncogene 35, 6177–6188 (2016).
pubmed: 27157622
pmcid: 5143367
doi: 10.1038/onc.2016.157
Qian, Z., Gong, L., Mou, Y., Han, Y. & Zheng, S. MicroRNA-203a-3p is a candidate tumor suppressor that targets thrombospondin 2 in colorectal carcinoma. Oncol. Rep. 42, 1825–1832 (2019).
pubmed: 31545460
pmcid: 6775819
Zu, F. et al. Identification of a competing endogenous RNA axis related to gastric cancer. Aging (Albany, NY). 12, 20540–20560 (2020).
pubmed: 33080572
pmcid: 7655175
doi: 10.18632/aging.103926
Yang, Y. et al. MiR-221-3p is down-regulated in preeclampsia and affects trophoblast growth, invasion and migration partly via targeting thrombospondin 2. Biomed. Pharmacother. 109, 127–134 (2019).
pubmed: 30396069
doi: 10.1016/j.biopha.2018.10.009
Wu, X.-G. et al. Cancer-derived exosomal miR-221-3p promotes angiogenesis by targeting THBS2 in cervical squamous cell carcinoma. Angiogenesis 22, 397–410 (2019).
pubmed: 30993566
doi: 10.1007/s10456-019-09665-1
Wei, W. F. et al. MicroRNA-221-3p, a TWIST2 target, promotes cervical cancer metastasis by directly targeting THBS2 article. Cell Death Disease 8, (2017).
Du, P., Lai, Y.-H., Yao, D.-S., Chen, J.-Y. & Ding, N. Downregulation of microRNA-1246 inhibits tumor growth and promotes apoptosis of cervical cancer cells by targeting thrombospondin-2. Oncol. Lett. 18, 2491–2499 (2019).
pubmed: 31404330
pmcid: 6676746
Chen, J. et al. MiR-1246 promotes SiHa cervical cancer cell proliferation, invasion, and migration through suppression of its target gene thrombospondin 2. Arch. Gynecol. Obstet. 290, 725–732 (2014).
pubmed: 24806621
doi: 10.1007/s00404-014-3260-2
Fiedler, J. et al. Identification of miR-143 as a major contributor for human stenotic aortic valve disease. J. Cardiovasc. Transl. Res. 12, 447–458 (2019).
pubmed: 30840186
doi: 10.1007/s12265-019-09880-7
Tiago, D. M., Conceição, N., Caiado, H., Laizé, V. & Cancela, M. L. Matrix Gla protein repression by MIR-155 promotes oncogenic signals in breast cancer MCF-7 cells. FEBS Lett. 590, 1234–1241 (2016).
pubmed: 27009385
doi: 10.1002/1873-3468.12155
He, X. et al. Indoxyl sulfate promotes osteogenic differentiation of vascular smooth muscle cells by miR-155-5p-dependent downregulation of matrix Gla protein via ROS/NF-κB signaling. Exp. Cell Res. 397, 112301 (2020).
pubmed: 32979364
doi: 10.1016/j.yexcr.2020.112301
Jiang, K. et al. MiR-155-5p promotes oxalate- and calcium-induced kidney oxidative stress injury by suppressing MGP expression. Oxid. Med. Cell Longev. 2020, 1 (2020).
Qiu, C.-Z. et al. Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer. World J. Gastroenterol. 12, 2011–2015 (2006).
pubmed: 16610049
pmcid: 4087677
doi: 10.3748/wjg.v12.i13.2011
Kubista, M. et al. The real-time polymerase chain reaction. Mol. Aspects Med. 27, 95–125 (2006).
pubmed: 16460794
doi: 10.1016/j.mam.2005.12.007
Peltier, H. J. & Latham, G. J. Normalization of microRNA expression levels in quantitative RT-PCR assays: Identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA 14, 844–852 (2008).
pubmed: 18375788
pmcid: 2327352
doi: 10.1261/rna.939908
Mostaço-Guidolin, L. B. et al. Collagen morphology and texture analysis: from statistics to classification. Sci. Rep. 3, 2190 (2013).
pubmed: 23846580
pmcid: 3709165
doi: 10.1038/srep02190
Amin, A. & Mahmoud-Ghoneim, D. Texture analysis of liver fibrosis microscopic images: A study on the effect of biomarkers. Acta Biochim. Biophys. Sin. (Shanghai) 43, 193–203 (2011).
pubmed: 21258076
doi: 10.1093/abbs/gmq129
Zheng, Y. et al. Adaptive color deconvolution for histological WSI normalization. Comput. Methods Programs Biomed. 170, 107–120 (2019).
pubmed: 30712599
doi: 10.1016/j.cmpb.2019.01.008
Pérez-Bueno, F. et al. Blind color deconvolution, normalization, and classification of histological images using general super Gaussian priors and Bayesian inference. Comput. Methods Programs Biomed. 211, 106453 (2021).
pubmed: 34649072
doi: 10.1016/j.cmpb.2021.106453
Petitjean, M. M. Systems and methods for quantitative phenotyping of fibrosis. US11430112 (Patent) 2022.
Nakamura, Y. et al. Automated fibrosis phenotyping of liver tissue from non-tumor lesions of patients with and without hepatocellular carcinoma after liver transplantation for non-alcoholic fatty liver disease. Hepatol. Int. 16, 555–561 (2022).
pubmed: 35553006
doi: 10.1007/s12072-022-10340-9
Wang, S. et al. An autocrine signaling circuit in hepatic stellate cells underlies advanced fibrosis in nonalcoholic steatohepatitis. Sci. Transl. Med. 15, eadd3949 (2023).
pubmed: 36599008
pmcid: 10686705
doi: 10.1126/scitranslmed.add3949
Roth, J. D. et al. INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis. World J. Gastroenterol. 24, 195–210 (2018).
pubmed: 29375205
pmcid: 5768938
doi: 10.3748/wjg.v24.i2.195
Inia, J. A. et al. Semaglutide has beneficial effects on non-alcoholic steatohepatitis in Ldlr−/−. Leiden mice. Int. J. Mol. Sci. 24, 8494 (2023).
pubmed: 37239841
pmcid: 10218334
doi: 10.3390/ijms24108494
Hinz, B. et al. Recent developments in myofibroblast biology: Paradigms for connective tissue remodeling. Am. J. Pathol. 180, 1340–1355 (2012).
pubmed: 22387320
pmcid: 3640252
doi: 10.1016/j.ajpath.2012.02.004
Kelly, T., Huang, Y., Simms, A. E. & Mazur, A. Fibroblast activation protein-α: A key modulator of the microenvironment in multiple pathologies. Int. Rev. Cell Mol. Biol. 297, 83–116 (2012).
pubmed: 22608558
doi: 10.1016/B978-0-12-394308-8.00003-0
Odze, R. D. A contemporary and critical appraisal of ‘indeterminate colitis’. Mod. Pathol. 28, S30–S46 (2015).
pubmed: 25560598
doi: 10.1038/modpathol.2014.131
Rippa, A. L., Kalabusheva, E. P. & Vorotelyak, E. A. Regeneration of dermis: Scarring and cells involved. Cells 8, 607 (2019).
pubmed: 31216669
pmcid: 6627856
doi: 10.3390/cells8060607
Driskell, R. R. et al. Distinct fibroblast lineages determine dermal architecture in skin development and repair. Nature 504, 277–281 (2013).
pubmed: 24336287
pmcid: 3868929
doi: 10.1038/nature12783
Woodley, D. T. Distinct fibroblasts in the papillary and reticular dermis: Implications for wound healing. Dermatol. Clin. 35, 95–100 (2017).
pubmed: 27890241
doi: 10.1016/j.det.2016.07.004
Leavitt, T. et al. Scarless wound healing: Finding the right cells and signals. Cell Tissue Res. 365, 483–493 (2016).
pubmed: 27256396
pmcid: 5010960
doi: 10.1007/s00441-016-2424-8
Mukherjee, P. K. et al. Stricturing Crohn’s disease single-cell RNA sequencing reveals fibroblast heterogeneity and intercellular interactions. Gastroenterology 165, 1180–1196 (2023).
pubmed: 37507073
doi: 10.1053/j.gastro.2023.07.014
Shu, W. et al. Single-cell expression atlas reveals cell heterogeneity in the creeping fat of Crohn’s disease. Inflamm. Bowel Dis. 29, 850–865 (2023).
pubmed: 36715181
doi: 10.1093/ibd/izac266